Gather detailed information on the health and treatment of patients with severe asthma worldwide, track how well patients are responding to treatment, and undertake medical research using data from the registry to improve asthma treatment and care.

This registry will collect data on the strategies used to achieve a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) and Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype (ILD) and the treatment and management efforts applied throughout study follow-up, clinical outcome events and patient reported outcome data. Blood samples will be collected periodically throughout the study for use in future research efforts. For participants with non-IPF, chronic fibrosing ILD with progressive phenotype, HRCT images will be collected throughout the study for use in future research efforts.

To 1) measure and improve the quality of care, 2) determine the clinical effectiveness, comparative effectiveness, and cost effectiveness of treatment approaches, 3) understand risk factors for outcomes , and 4) facilitate funded clinical trials of new therapies and collaboration within the pulmonary arterial hypertension (PAH) community.

The purpose of this trial is to allow patients who are currently on the PROSERA trial to receive medication until the study drug is commercially available.

This study will test how effectively changes in lung structure and function can be detected with a new inhaled gas combined with a MRI.

Hypothesis: The development of patient-focused tools and care processes will enable a transition from predominantly office-based CF care to a more convenient, co-produced model. The increased utilization of remote care will be associated with improved adherence to disease monitoring and complication screening guidelines and will increase patient satisfaction. Specific Aims: 1. Customize a patient-facing smartphone application (Nudge) designed to "coach" each patient toward a co-produced goal of convenient and effective health monitoring within the context of enhanced remote care. 2. Develop care processes that facilitate monitoring of respiratory status at home, using home spirometry and remote sputum collection, that include education, electronic reminders, and specimen collection/shipping supplies 3. Implement care processes that allow convenient access to necessary screening procedures, using the Nudge application to provide well-timed electronic reminders and track performance of screening tests.

This study hopes to identify barriers to care for patients with interstitial lung disease by surveying patient experiences with symptoms, diagnosis, ongoing treatment of their lung disease.

The virus that causes COVID-19 disease infects many people, but only some get sick. We want to understand how COVID affects the immune system and what makes severe COVID infections different from other diseases that cause hospitalization and breathing problems. We collect samples of blood, sputum, urine, and stool from patients in the hospital to learn how COVID affects cells and molecules of the immune system.

The primary objective of PATIENCE is to develop a standardized approach to the treatment of NTM in CF patients with a diagnosis of NTM disease. The secondary objectives are to: - Evaluate the feasibility and tolerability of a standardized treatment protocol for NTM disease - Evaluate effectiveness of a standardized NTM disease treatment protocol to serve as baseline/reference estimates of endpoints in clinical care and future therapeutic trials - Support biomarker development for markers of NTM treatment response through banking of clinical specimens and NTM isolates linked with outcomes data - Characterize clinical features of patients achieving treatment success compared to those unresponsive to treatment

The purpose of this study is to evaluate a new test being developed by Tempus for patients with Non-Small Cell Lung Cancer (NSCLC). The goal of this new test is to predict the likelihood of a patient's cancer coming back after treatment, and to further explore changes in patient's tumors throughout treatment to see how they respond.